昊帆生物
(301393)
| 流通市值：27.59亿 | | | 总市值：67.78亿 |
| 流通股本：4396.77万 | | | 总股本：1.08亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 379,224,583 | 171,932,875.31 | 602,261,319.28 | 434,698,213.66 |
| 营业收入 | 379,224,583 | 171,932,875.31 | 602,261,319.28 | 434,698,213.66 |
| 二、营业总成本 | 308,734,317.86 | 140,790,057 | 485,012,926.06 | 336,820,135.14 |
| 营业成本 | 244,932,999.64 | 110,891,430.64 | 392,510,570.71 | 266,268,640.36 |
| 税金及附加 | 4,258,122.6 | 1,647,328.41 | 6,604,271.85 | 4,667,491.6 |
| 销售费用 | 9,065,170.26 | 3,898,874.45 | 16,392,168.35 | 12,726,014.71 |
| 管理费用 | 24,213,728.17 | 12,469,471.41 | 36,854,852.51 | 30,740,506.56 |
| 研发费用 | 23,331,753.66 | 10,685,900.81 | 40,928,280.5 | 30,612,903.47 |
| 财务费用 | 2,932,543.53 | 1,197,051.28 | -8,277,217.86 | -8,195,421.56 |
| 其中:利息费用 | 316,395.58 | 152,492.53 | 698,037.91 | 504,290.66 |
| 其中:利息收入 | 3,511,221.22 | 2,295,656.68 | 16,468,599.34 | 12,832,185.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 8,724,102.75 | 4,532,114.61 | 7,240,295.4 | 7,813,884.37 |
| 加:投资收益 | 2,106,998.69 | 1,255,693.12 | 17,251,963.74 | 12,609,547.77 |
| 资产处置收益 | 124,539.26 | 58,841.59 | -907,512.14 | -93,989.15 |
| 资产减值损失(新) | 81,998.61 | -626,884.4 | -6,602,917.21 | -13,243,008.25 |
| 信用减值损失(新) | -2,950,486.41 | -1,087,472.05 | 2,357,860.4 | 3,740,734.34 |
| 其他收益 | 3,075,664.1 | 2,411,926.8 | 7,667,041.29 | 5,894,088.12 |
| 四、营业利润 | 81,653,082.14 | 37,687,037.98 | 144,255,124.7 | 114,599,335.72 |
| 加:营业外收入 | 23,775.15 | 18,436.71 | 172,233 | 116,822.93 |
| 减:营业外支出 | 223,159.01 | 75,730.21 | 15,157,159.4 | 889,406.87 |
| 五、利润总额 | 81,453,698.28 | 37,629,744.48 | 129,270,198.3 | 113,826,751.78 |
| 减:所得税费用 | 12,062,646.93 | 4,915,705.02 | 18,425,875.56 | 14,588,403.86 |
| 六、净利润 | 69,391,051.35 | 32,714,039.46 | 110,844,322.74 | 99,238,347.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 69,391,051.35 | 32,714,039.46 | 110,844,322.74 | 99,238,347.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 70,746,277.49 | 33,444,698.56 | 114,650,719.19 | 99,238,347.92 |
| 少数股东损益 | -1,355,226.14 | -730,659.1 | -3,806,396.45 | - |
| 扣除非经常损益后的净利润 | 60,379,920.89 | 27,792,400.54 | 104,433,657.15 | 81,271,955.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.66 | 0.31 | 1.07 | 0.93 |
| (二)稀释每股收益 | 0.66 | 0.31 | 1.07 | 0.92 |
| 八、其他综合收益 | 49,949.13 | 77,060.21 | 106,026.85 | 132,740.77 |
| 归属于母公司股东的其他综合收益 | 49,949.13 | 77,060.21 | 106,026.85 | 132,740.77 |
| 九、综合收益总额 | 69,441,000.48 | 32,791,099.67 | 110,950,349.59 | 99,371,088.69 |
| 归属于母公司股东的综合收益总额 | 70,796,226.62 | 33,521,758.77 | 114,756,746.04 | 99,371,088.69 |
| 归属于少数股东的综合收益总额 | -1,355,226.14 | -730,659.1 | -3,806,396.45 | - |
| 公告日期 | 2026-08-25 | 2026-04-24 | 2026-04-17 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |